

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

February 10, 2015

Bombay stock Exchange Limited  
1<sup>st</sup> Floor, P.J. Towers  
Dalal Street  
MUMBAI – 400 001

**Kind Attn.:** Mr. Kapoor  
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G Block  
Bandra-Kurla Complex  
Bandra – (East)  
Mumbai – 400 051

**Kind Attn.:** Famroze Pochara  
Asst. Vice President

Ahmedabad Stock Exchange Limited  
Kamdhenu Complex  
Opp. Sahajanand College  
Panjara Pole,  
Ahmedabad – 380 015

Dear Sirs

**Re.:** Unaudited financial results for the quarter and nine months ended on December 31, 2014.

We are forwarding herewith unaudited financial results for the quarter and nine months ended on December 31, 2014 reviewed by Audit Committee and taken on record by the Board of Directors on February 10, 2015 pursuant to Clause 41 of the Listing Agreement; the same may please receive in order.

Thanking you

Yours faithfully

For **CADILA HEALTHCARE LIMITED**

  
**UPEN H. SHAH**  
**COMPANY SECRETARY**

Encl.: As above



**Notes :**

- [1] The above results for the quarter/ nine months ended on December 31, 2014 were reviewed by the Audit Committee on February 9, 2015 and then approved by the Board of Directors at their meeting held on February 10, 2015.
- [2] The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per clause 41 of the Listing Agreement.
- [3] Effective from April 1, 2014, the Company has changed the depreciation charge based on the revised remaining useful lives of the assets as per the requirement of Schedule II of the Companies Act, 2013. Due to this, the depreciation charge for the quarter ended December 31, 2014 is higher by Rs. 1,613 Lacs on Standalone basis [Rs. 1,649 Lacs on Consolidated basis] and for the nine months ended December 31, 2014 is higher by Rs. 4,839 Lacs on Standalone basis [Rs. 5,325 Lacs on Consolidated basis]. Further, based on transitional provision provided in Note 7(b) of Schedule II, an amount of Rs. 2,497 Lacs on Standalone basis [Rs. 2,594 Lacs on Consolidated basis], which pertains to the carrying value of the assets whose remaining useful lives as on April 1, 2014 is "Nil", has been adjusted to the Retained Earnings.
- [4] Exceptional items in the consolidated results include:
 


No.	Particulars	Rupees In Lacs					
		3 Months ended 31/12/2014 (Unaudited)	Preceding 3 months ended 30/09/2014 (Unaudited)	Corresponding 3 months ended 31/12/2013 in the previous year (Unaudited)	Year to date figures for the current period ended 31/12/2014 (Unaudited)	Year to date figures for the previous year ended 31/12/2013 (Unaudited)	Previous year ended 31/09/2014 (Audited)
a	Provision for various expenses related to the closure of business operations in Japan	22	(23)	347	117	347	1,715
b	Provision for amount payable to a former supplier for termination of supply contract, pursuant to the order passed by the Honorable High Court of Madrid, Spain	1,070	0	0	1,070	0	0
c	Credit of additional excise duty (for the years 2011-12 to 2013-14) received by M/s. Zyklus Wellness, Sikkim, pursuant to the order passed by the Office of the Commissioner of Customs, Central Excise and Service Tax for the fixation of special rates of excise duty for the said 3 years	(1,553)	0	0	(1,553)	0	0
- [5] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.
- [6] The Company has one segment of activity viz., "Pharmaceuticals".

**PART II**

**Select information for the Quarter and Nine Months Ended 31/12/2014**

3 Months ended 31/12/2014	Preceding 3 months ended 30/09/2014	Corresponding 3 months ended 31/12/2013 in the previous year	Year to date figures for the current period ended 31/12/2014	Year to date figures for the previous year ended 31/12/2013	Previous year ended 31/09/2014												
51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%	51,610,474 25.21%												
Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.	Nil N.A. N.A.												
153,138,046 100.00%	153,138,046 100.00%	153,138,046 100.00%	153,138,046 100.00%	153,138,046 100.00%	153,138,046 100.00%												
74.79%	74.79%	74.79%	74.79%	74.79%	74.79%												
<table border="1" data-bbox="417 793 568 1678"> <thead> <tr> <th>Particulars</th> <th>3 months ended 31/12/2014</th> </tr> </thead> <tbody> <tr> <td><b>INVESTOR COMPLAINTS [In Numbers]</b></td> <td>Nil</td> </tr> <tr> <td>Pending at the beginning of the quarter</td> <td>7</td> </tr> <tr> <td>Received during the quarter</td> <td>7</td> </tr> <tr> <td>Disposed of during the quarter</td> <td>7</td> </tr> <tr> <td>Remaining unresolved at the end of the quarter</td> <td>Nil</td> </tr> </tbody> </table>						Particulars	3 months ended 31/12/2014	<b>INVESTOR COMPLAINTS [In Numbers]</b>	Nil	Pending at the beginning of the quarter	7	Received during the quarter	7	Disposed of during the quarter	7	Remaining unresolved at the end of the quarter	Nil
Particulars	3 months ended 31/12/2014																
<b>INVESTOR COMPLAINTS [In Numbers]</b>	Nil																
Pending at the beginning of the quarter	7																
Received during the quarter	7																
Disposed of during the quarter	7																
Remaining unresolved at the end of the quarter	Nil																

Ahmedabad, February 10, 2015

By Order of the Board,  
For Cadila Healthcare Limited,  
  
Paritaj R. Patel  
Chairman & Managing Director